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Abstract: Hypertension (HTN) is an important factor in progressive loss of renal function. 
The kidney can be both a contributor to and a target of HTN. The functional integrity of the 
kidney is vital for the maintenance of cardiovascular homeostasis. Chronic activation of the 
renin system causes HTN and, ultimately, end-organ damage. Direct renin inhibitors (DRIs) 
inhibit plasma renin activity (PRA), thereby preventing the conversion of angiotensinogen 
to angiotensin I; consequently, the levels of both Ang I and Ang II are reduced. There is no 
compensatory increase in PRA activity with DRIs as seen with angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). There are reasons to speculate 
that renin inhibition might prove to be a superior strategy for blocking the renin–angiotensin–
aldosterone system compared with ACEIs or ARBs. Evidence for the efficacy of aliskiren (a DRI) 
is considered to be relatively strong, based on published, short-term, double-blind,   randomized, 
controlled trials showing that aliskiren is as effective as other antihypertensive agents in reducing 
blood pressure (BP), with no rebound effects on BP after treatment withdrawal. When combined 
with diuretics, fully additive BP reduction is seen. When given with an ACEI or ARB, aliskiren 
produces significant additional BP reduction indicative of complimentary pharmacology and 
more complete renin–angiotensin system blockade.
Keywords: aliskiren, direct renin inhibitor, angiotensin-converting enzyme inhibitor, ACE 
inhibitor, angiotensin II receptor blocker, chronic kidney disease, hypertension, diabetes 
mellitus
Epidemiology of kidney disease in HTN
In the 18th century, Dr. Richard Bright, the father of nephrology who was physician 
to the Queen of England, and numerous other medical scientists, suspected that the 
kidney plays an important part in hypertension (HTN). A long-held view is that the 
kidney is somehow involved in the mechanisms of HTN. The precise stimulus that elicits 
HTN is still uncertain. But, there are vast amounts of valuable information about the 
mechanisms of HTN once this process has started. The kidney is an important target 
organ for HTN-related injury.1
HTN is an important factor in progressive loss of renal function.   Epidemiology 
has provided sound scientific evidence for the core concepts of progressive renal 
  damage secondary to HTN. Multiple risk factors, such as age, atherosclerosis, 
  diabetes, and race, are associated with progressive damage to the kidney. Because of 
its major   contribution to HTN-related renal damage, diabetes has been a major focus 
of   epidemiological   studies. Improved medical care for patients with chronic renal 
disease has   contributed to annual increases in the number of patients who survive with Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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end-stage renal disease (ESRD). Most patients with ESRD 
have HTN, and most forms of renal disease are   associated 
with HTN.2,3 HTN is most evident with   glomerular   diseases, 
in which 70%–80% of patients are affected,   including dia-
betic nephropathy (DN), membranous glomerulonephritis, 
membranoproliferative glomerulonephritis, and focal seg-
mental   glomerulonephritis. Minimal change nephropathy 
is a notable exception. Tubulointerstitial disorders, such as 
analgesic nephropathy, chronic interstitial nephritis, medul-
lary cystic diseases, and chronic reflux nephropathies, are 
less commonly associated with HTN.4
Risk factors for progression  
of chronic kidney disease
Among the 332,544 men screened for the Multiple Risk 
Factor Intervention Trial from the year 1973–1975, older 
age, lower income, higher serum cholesterol concentrations, 
cigarette smoking, diabetes mellitus (DM), a history of HTN, 
and black race were also found to be associated with an 
increased risk of ESRD.
The third National Health and Nutrition   Examination 
Survey has added new insights to serum creatinine and 
  hemoglobin concentrations as risk factors for ESRD. 
  Intervention trials for each risk factor that can be modified 
have not been completed. Accordingly, improvements in 
certain risk factors (eg, anemia) have not been shown to 
impact on the   progression of renal disease.2
HTN and chronic kidney disease: 
hemodynamic abnormalities
In parenchymal renal disease, multiple factors can influ-
ence cardiac output, systemic vascular resistance, or 
both. Blood pressure (BP) is the product of cardiac out-
put multiplied by total peripheral vascular resistance. In 
most patients with chronic renal failure, studies suggest 
that cardiac output is normal or elevated, whereas overall 
extracellular fluid volume is expanded. Systemic vascular 
resistance is inappropriately elevated relative to cardiac 
output, reflecting a net shift in vascular control toward 
vasoconstriction.
Several factors affecting vascular tone are disturbed 
in patients with chronic renal failure, including increased 
adrenergic tone and activation of the renin–angiotensin 
system (RAS), endothelin, and vasoactive prostaglandins. 
An additional feature in some disorders appears to depend 
on reduced vasodilation, such as in impaired production of 
nitric oxide (NO).3
HTN and chronic kidney disease: 
mechanisms
The functional integrity of the kidney is vital for the 
  maintenance of cardiovascular homeostasis. The nephron, 
comprised of the glomerulus and the tubules, is the primary 
functional unit of the kidney. The kidney plays a critical role in 
the long-term regulation of BP. Thus, pathological abnormali-
ties primary to the kidney may lead to an elevation of BP. As a 
corollary, HTN due to nonrenal causes can damage the kidney. 
The resulting loss of renal mass, in turn, can secondarily lead to 
further elevations in BP. The kidney can be both a contributor 
to and a target of HTN. Systemic BP elevation is associated 
with increased vascular tone due to decreased production or 
action of vasodilator molecules, such as endothelium-derived 
NO and prostacyclin (PgI2). At the same time, there is either 
maintenance or increased production of vasoconstrictors such 
as angiotensin II (Ang II) and endothelin-1. This imbalance is 
often termed endothelial dysfunction.
Increased renal sympathetic nerve activity may   contribute 
to vasoconstriction and augment tubular reabsorption of 
sodium. Many of the molecules promoting vasoconstriction 
also cause long-term effects on the nephron by   promoting 
growth of vascular smooth muscle cells (VSMCs) and mesan-
gial cells, decreasing apoptosis, stimulating   chemotaxis 
of vascular inflammatory cells into the vessel wall and 
the   tubular interstitium, and stimulating the production of 
  molecules that expand and alter the composition of the 
extracellular matrix in the mesangium and interstitium. The 
resulting glomerular HTN can lead to glomerular basement 
membrane damage and proteinuria.
Other conditions, such as DM, may also contribute to the 
glomerular basement membrane damage caused by HTN or 
may induce it independently through alteration of basement 
membrane proteins. Both glomerular HTN and proteinuria 
are associated with oxidative stress that can cause activation 
of circulating leukocytes and their diapedesis into the vessel 
wall and interstitium and can stimulate the release of cytokines 
and growth factors that lead to extracellular matrix formation, 
progressive sclerosis of both the glomerulus and tubules, and 
ultimately, loss of nephron units. When the compensatory 
capacity of the remaining nephrons is exceeded, renal function 
progressively deteriorates and renal failure develops.5–9
Consequences of renal  
damage in HTN
Functional changes that result from HTN include a decline 
in glomerular filtration rate (GFR) and abnormalities in 
tubular function, including new onset or worsening of Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  proteinuria. These functional changes lead to structural 
changes in the glomerular basement, expansion of the 
mesangial and   interstitial matrix, ultimately resulting in 
sclerosis of both glomerular and tubular elements.5–9   Vascular 
endothelium, under normal conditions, is an important 
source of   vasodilators such as NO, PgI2, and one or more 
endothelium-derived hyperpolarizing factors (EDHFs) that 
are not yet chemically characterized. Endothelium-derived 
NO has many functions. Among them are VSMC relaxation, 
modulation of renal medullary blood flow, inhibition of 
VSMC growth, inhibition of platelet aggregation,   inhibition 
of polymorphonuclear (PMN) leukocyte and monocyte (MF) 
adhesion molecule expression and immigration into the 
  vascular wall and interstitium, and augmentation of apoptosis 
or programmed cell death. The formation or the actions of 
endothelium-derived NO are blunted in patients with HTN. 
This impairment may be more exaggerated in patients with 
concomitant DM. NO shares many of its actions in the 
  vasculature and in the kidney with PgI2 or other EDHFs.5–9
Imbalance in factors affecting 
vascular tone and structure
HTN is associated with an altered balance in the   elaboration 
or biological action of vasodilator and vasoconstrictor 
molecules. The production of vasodilators like PgI2 and 
NO is diminished in HTN, whereas the production of 
catecholamines, reactive oxygen species (ROS), Ang II, 
endothelin-1, and other endothelium-derived constricting 
factors is either maintained or increased.
Many of the molecules that augment vascular tone also 
have long-term mitogenic effects on VSMCs and glomerular 
mesangial cells, activate adhesion molecules on leukocytes 
and platelets with resulting influx of these cells into the 
vessel wall, decrease apoptosis, and stimulate   extracellular 
(  interstitial and mesangial) matrix formation, whereas 
molecules that promote vasodilation tend to inhibit these 
processes.10–14
ROS reduces the biological  
effects of NO
The potent vasodilator molecule, NO, is produced by 
  constitutively expressed endothelial NO synthase from 
l-arginine via a 5-electron redox reaction. NO also inhibits 
VSMC proliferation and migration, mononuclear (MF) and 
PMN leukocyte adhesion molecule expression, and platelet 
aggregation. Injured VSMCs or endothelial cells; activated 
vascular wall mast cells, fibroblasts, macrophages, and 
  leukocytes; and oxidation of norepinephrine (NE) from 
renal sympathetic nerves produce increased amounts of 
ROS that then interact with NO to form the potent cytotoxic 
  peroxynitrite radical (OONO-). This radical interacts with 
proteins in the kidney that are important for normal   glomerular 
and tubular functions to reduce their activities.15–17
Renin–angiotensin cascade
Activation of the renin system occurs following the release 
of renin from juxtaglomerular apparatus within the kidney. 
Renin cleaves the circulating angiotensinogen to   angiotensin 
I (Ang I); Ang I itself is inactive, but is converted to the 
  biologically active peptide Ang II by the ACE, which is 
  produced in the lungs. Ang II is a vasoconstrictor; it binds 
with type I Ang II (AT1) receptors in the SMCs of the 
peripheral blood   vessels causing vasoconstriction and, 
consequently, increased   peripheral vascular resistance and 
increased BP. Activation of AT1 receptors by Ang II also 
stimulates the release of aldosterone from the adrenal gland, 
which promotes retention of sodium and water along the 
nephron, further increasing BP (  Figure 1). In pathologic 
  conditions, the renin system can become   chronically   activated 
as increases in renin system activity lead to increased BP, 
and then chronic activation of the renin system causes HTN 
and ultimately end-organ damage.
There are at least two alternative pathways for Ang II 
  formation that do not rely on either renin or ACE. In the non-
renin pathway, tissue plasminogen activator (tPA) forms Ang 
II directly from angiotensinogen, bypassing the   renin-mediated 
production of Ang I as an intermediate.
A second alternative pathway involves enzymes like 
chymase that can form Ang II from Ang I via an ACE-
independent mechanism. These alternative pathways are 
implicated in the gradual return toward pretreatment Ang II 
concentrations during treatment of patients with angiotensin-
converting enzyme inhibitors (ACEIs) and provide a rationale 
for considering angiotensin receptor blockers (ARBs) that 
directly inhibit the binding of Ang II to the AT1 receptor 
either in conjunction with or as an alternative to ACEI 
therapy.18,19
Ang II and kidney diseases
Ang I formed in the afferent arteriole via the action of 
renin synthesized and secreted by the modified VSMCs 
in the arteriolar tunica media (juxtaglomerular cells) then 
  interacts with ACE, a membrane bound enzyme on the 
luminal plasma membrane of the endothelial cells to form 
Ang II. Ang II can bind to and activate angiotensin AT1 
receptors located on VSMCs, endothelial cells, tubular cells, Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Figure 1 The renin–angiotensin cascade and the three available approaches to pharmacologic inhibition of production or action of angiotensin II.
Abbreviations: DRI, direct renin inhibitors; ACeI, angiotensin-converting enzyme inhibitor; ARB, angiotensin (AT) type 1 receptor blockers.
and mesangial cells. Binding of Ang II to afferent arteriolar 
juxtaglomerular cell AT1 receptor further diminishes renin 
production, thus, providing an intrarenal feedback loop for 
the control of renin secretion and Ang II generation.20 Ang II 
plays a pivotal role in pathological processes in HTN that 
ultimately leads to renal glomerular and tubular   destruction 
and renal failure. Ang II, acting either through signal 
  transducing mechanisms or directly on cells to stimulate 
the production or activation of mediators, causes infiltration 
of inflammatory cells or increased production of mesangial 
and interstitial matrix with resultant glomerular and   tubular 
injuries and destruction (nephron loss). The remaining 
normal nephrons are forced to compensate by increasing 
filtration rate, which (in the presence of increased Ang II) 
increases glomerular capillary pressure and perpetuates this 
progressive spiral of deteriorating renal function.21 Ang II 
stimulates several key enzymes or cytokines in vascular 
and tubular cells within the kidney to produce increased 
amounts of ROS. In addition, Ang II activates NF-kB, a 
nuclear factor pivotal to the production of inflammatory 
cytokines. These cytokines exert their effects, in part, 
through oxidative mechanisms.12
Aldosterone promotes renal fibrosis   
by multiple mechanisms
The potent mineralocorticoid, aldosterone, is produced by the 
adrenal zona glomerulosa in response to Ang II   stimulation. 
There is also evidence that the myocardium, vascular 
  endothelial cells and SMCs are capable of synthesizing 
aldosterone. Aldosterone has been implicated in vascular, 
myocardial, and renal fibrosis that occurs in patients with 
  arteriosclerosis, congestive heart failure, and renal failure, 
particularly if HTN is also present and is accompanied by 
activation of the renin–angiotensin–aldosterone system 
(RAAS).
The mechanisms by which aldosterone contributes to 
vascular and renal fibrosis are not well understood, but there 
are several experimental findings that support the mecha-
nisms. Aldosterone has been reported to augment affinity of 
Ang II for the AT1 receptor, thereby enhancing the pressor 
effects of Ang II; augment the influx of sodium into VSMCs, 
contributing to VSMC hypertrophy;22 potentiate the action 
of NE by inhibiting its uptake into VSMCs; contribute to 
endothelial dysfunction by inhibiting NO synthesis; stimulate 
the production of plasminogen activator inhibitor-1, which 
promotes fibrosis; and promote synthesis of Type I collagen 
by interstitial fibroblasts.23–29
Pathways leading to progressive 
renal failure
Both hypertensive and nonhypertensive injuries that cause 
loss of single nephron units result in HTN in the remaining 
glomeruli (glomerular HTN).
Glomerular HTN can lead to injury to the glomerular 
basement membrane, causing it to leak plasma proteins in the 
urine. The proximal tubules attempt to reabsorb this filtered 
protein. This causes injury to the tubular cells, activates an 
inflammatory response, and is associated with the develop-
ment of lipid metabolic abnormalities that create further 
oxidative stress on the already compromised glomerulus. 
The resultant tubular inflammatory response and renal 
microvascular injury activate pathways that lead to fibrosis 
and scarring of both glomerular and tubular elements of the 
nephron.
An additional consequence of glomerular HTN and resul-
tant reduction in GFR activates growth factors and cytokines. 
This promotes an influx of monocytes and macrophages 
into the vessel wall and into the renal interstitium as well as 
differentiation of renal cells into the fibroblasts.   Monocytes, 
macrophages, and fibroblasts are capable of producing those Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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growth factors and cytokines that activate pathways leading 
to expansion of extracellular matrix, fibrosis, and loss of both 
tubular and glomerular structures.
HTN and renal parenchymal diseases are closely inter-
related. Primary renal diseases eventually disrupt sodium and 
volume control to produce clinical HTN. Activation of the 
RAS, adrenergic nervous system, and endothelin can enhance 
vasoconstriction and mediate tissue injury by the promotion 
of inflammatory cytokines and interstitial fibrosis. Arterial 
HTN accelerates renal disease and hastens the progression 
to end-stage renal failure.
The dual significance of proteinuria
In patients with proteinuric renal diseases, the rate of progres-
sion of renal insufficiency is determined by the level of BP 
and proteinuria. The reduction of BP and proteinuria has a 
beneficial impact on renal risk. Observational studies30,31 have 
also demonstrated that proteinuria is a marker for systemic 
vascular injury. It is hoped that efforts to reduce proteinuria 
and control BP will improve cardiovascular risk and reduce 
mortality. In this belief, the National Kidney Foundation 
and the American Diabetes Association have revised their 
recommendations for management of high-risk patients for 
tighter BP control to ,130/80 mmHg.32–39,33
Renal disease in HTN: core 
concepts of treatment
BP levels are reliable predictors of renal outcome. Absolute 
systolic and diastolic BP levels correlate with renal risk. 
In patients with renal disease, BP reduction clearly affects 
renal outcome. Proteinuria is an independent predictor of 
progression of renal disease, independent of absolute BP 
levels. In patients with and without diabetes, BP reduction 
provides protection against a progressive decline in renal 
function. The absolute level of BP reduction is important. 
African Americans may be at greater risk compared with 
other racial or ethnic groups. Relative renal hypoperfusion 
during initial stages of HTN correlates with a transient limited 
increase in serum creatinine; however, this phenomenon has 
become a deterrent to effective therapy rather than a hallmark 
of appropriate antihypertensive management. The reduction 
of BP and proteinuria has an impact on both cardiovascular 
and renal risk for, thus far, unexplained reasons.
Management of risk factors in HTN 
and chronic kidney disease
Current National Kidney Foundation recommendations for 
the management of patients with HTN and chronic kidney 
disease (CKD) include antihypertensive therapy to reduce 
BP to goal values, use of lipid-lowering drugs to reduce 
low-density lipoprotein cholesterol and triglycerides to goal 
values, and smoking cessation. Recent evidence indicates 
that anemia may also have a deleterious influence on the 
incidence of cardiovascular events and on death in patients 
with chronic renal insufficiency. Similar observations have 
been made for abnormalities of calcium and phosphorus. 
The beneficial consequences of treating the last two risk 
  factors for cardiovascular events in patients with chronic renal 
  disease are less well defined than are the beneficial effects of 
aggressively managing the first three risk factors.40–42
Proteinuria reflects injury to glomerular capillary 
endothelial cell basement membranes, allowing the 
  extravasation of protein from the vascular compartment into 
the urine. In patients with HTN and diabetes, this process 
probably also occurs in other vascular beds in addition to the 
renal vascular bed. This pathological process may explain 
why patients with proteinuria are at increased cardiovascular 
risk. Although important, aggressive management of HTN in 
patients with chronic renal disease and proteinuria is not suf-
ficient. In   addition to the landmark trial by Lewis et al dem-
onstrating that the ACEI captopril reduced both the combined 
primary end point (time to doubling of serum creatinine, 
death or the need for dialysis) and proteinuria in patients 
with type 1 diabetes, other clinical trials   involving fewer 
numbers of patients have also demonstrated a   beneficial effect 
of ACEIs and ARBs on proteinuria in patients with   diabetes 
and in hypertensive and normotensive patients   without 
diabetes with immunoglobulin nephropathy.49 Although 
the   dose-dependency of this effect of ACEIs and ARBs on 
protein has not been extensively examined, dose-titration of 
agents from either class seems warranted in patients with 
proteinuria, to monitor for possible adverse effects as the 
dosage is increased.
There are limited but encouraging data to suggest that 
combination of an ACEI and ARB may be more   effective 
than either agent alone in reducing proteinuria. Drugs from 
other antihypertensive classes appear to have less effect 
on   proteinuria than ACEIs and ARBs. In fact, certain 
  dihydropyridine calcium channel blockers (CCBs) have 
been associated with worsening of proteinuria.   Management 
of identified cardiovascular risks is just as important in 
the hypertensive patient with chronic renal disease as in 
the patient with diabetes. This includes drugs and diet to 
maintain a normal lipid profile; adequate control of BP, 
dietary protein, and sodium restriction; smoking cessation; 
reduction of overweight to normal body mass index; and Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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a regular aerobic exercise program. Patients with anemia 
are at increased cardiovascular risk, and early initiation of 
  erythropoietin and iron therapies for those that are erythro-
poietin and iron deficient, respectively, is warranted. Patients 
with hyperhomocysteinemia may be candidates for folic acid 
therapy.43–47,33
The management of HTN and chronic renal disease in 
patients with diabetes should be even more aggressive than 
in the patients without diabetes. The goal of antihypertensive 
therapy should be BP values ,130/80 mmHg, except in those 
patients with diabetes who have .1 g/d of proteinuria. In 
the latter patients, the goal BP should be ,125/75 mmHg. 
Multiple antihypertensive drugs will usually be required to 
achieve these BP goals. Drugs or drug combinations that are 
most effective in reducing or abolishing proteinuria should 
be used and the doses should be modified based on frequent 
determination of urine protein, until the desired effect is 
achieved.
Effective risk factor management of patients with diabetes 
also includes control of hyperlipidemia and hyperglycemia. 
Modest dietary protein restriction is recommended for the 
hypertensive patients with diabetes whose creatinine clear-
ance is already diminished. Sodium restriction is indicated 
in patients with CRD and impaired ability to excrete sodium. 
Smoking cessation is a key to successful cardiovascular risk 
reduction.43–47,33
CKD: initial treatment 
recommendations
In randomized clinical trials of patients with both diabetic 
and nondiabetic chronic renal disease, ACEIs and ARBs have 
frequently been more effective than other antihypertensive 
agents in ameliorating a progressive decline in renal function 
and reducing proteinuria even when comparable reduction in 
BP is achieved. In Microalbuminuria, Cardiovascular, and 
Renal Outcomes – Heart Outcomes Prevention Evaluation 
(MICRO-HOPE),  48 which was a substudy of the HOPE 
study, among patients with diabetes at high risk of cardiovas-
cular events, treatment with ramipril lowered the incidence of 
the development of overt nephropathy. In Irbesartan Diabetic 
Nephropathy Trial49 among patients with type 2 diabetes, 
the ARB irbesartan demonstrated a significantly decreased 
incidence of end points assessing the progression of renal 
disease compared with amlodipine and placebo. These effects 
appeared to be independent of irbesartan’s effects in lowering 
BP. In Renal and Cardiovascular Outcomes in Patients with 
Type 2 Diabetes and Nephropathy Trial,50 losartan conferred 
significant renal benefits in patients with type 2 diabetes and 
nephropathy. The observed decrease in progression of renal 
failure corresponded to an average of 2-year delay in need 
for dialysis or transplantation in losartan group vs placebo 
group.50
For these reasons, it is currently recommended that initial 
therapy of patients with microalbuminuria or macroalbu-
minuria, laboratory evidence by either creatinine clearance 
or serum creatinine measurements of renal insufficiency or 
with diabetes regardless of the level of renal function include 
an ACEI or ARB. Numerous studies have suggested benefits 
of dual RAS blockade in patients with albuminuria when 
compared with either an ARB or an ACEI monotherapy.51 
In a thorough meta-analysis of 49 studies involving over 
6,000 patients, Kunz et al52 found “encouraging” evidence 
that dual RAS blockade reduced proteinuria by 20%–25% 
more than either drug alone.52 The most recent landmark 
study, the Renal Outcomes with Telmisartan, Ramipril, or 
Both, in People at High Vascular Risk study,53 is no exception 
in this regard. The increase in albuminuria was reduced with 
a combination of telmisartan and ramipril when compared 
with monotherapy, but worsened major renal outcomes 
overall. This raises many questions about the relationship 
between proteinuria and renal failure that must be answered 
in future trials.
Escape of Ang II despite  
ACE inhibition
A growing body of evidence suggests that despite   effective 
inhibition of Ang II activity, the non-ACE synthetic   pathways 
still permit Ang II generation via serine proteases such as chy-
mase, cathepsin G, and tPA. ARBs block the AT1   receptor 
that transduces many of the known physiologic actions of 
Ang II. Other Ang II receptors, whose functions are less 
well defined, exist and are not blocked by ARBs. In this 
study, 19 hypertensive patients were treated with increasing 
doses of enalapril. The investigators concluded that the use 
of enalapril 20 twice daily effectively reduced BP but did 
not constantly suppress plasma Ang II and aldosterone. This 
phenomenon of the return of plasma Ang II to pretreatment 
values despite continued inhibition of ACE has been called 
angiotensin escape.54
Uniqueness of direct renin inhibition
The emergence of the direct renin inhibitors (DRIs) has 
afforded clinicians a new strategy for RAS blockade. In out-
comes studies that have used ACEIs or ARBs, there has been 
a relatively high residual event rate in the treatment arm, 
and this has been ascribed to the fact that neither ACEIs nor Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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ARBs completely repress RAS. For this reason, combined 
RAS blockade with an ACEI and ARB has emerged as a 
therapeutic option. In HTN, combined RAS blockade elicits 
only a marginal incremental drop in BP and it does not further 
lower the risk for cardiovascular events.55
DRIs represent a new class of antihypertensive agents 
that act on the renin system at its point of activation. DRIs 
have a unique effect on the components of the system. 
DRIs inhibit the activity of renin, thereby preventing the 
  conversion of angiotensinogen to Ang I and reducing plasma 
renin activity (PRA) consequently; DRIs reduce the level 
of both Ang I and Ang II. Similar to ACEIs and ARBs, the 
activity of   negative feedback loop is reduced with DRIs and 
renin release is increased; however, unlike with ACEIs and 
ARBs, the   activity of the released renin is inhibited by DRIs. 
Consequently, there is no compensatory increase in renin 
system activity with DRIs, and this is reflected by the level of 
PRA, which decreases in the presence of DRIs. The clinical 
implications of the reduction in PRA with DRIs vs an increase 
with ACEIs and ARBs are not known at   present. Aliskiren 
(DRI) is a newer agent that inhibits renin, the rate-limiting 
step in the RAAS. There are several theoretical reasons to 
suggest that aliskiren may have a protective action superior 
to those of ACEIs and ARBs.
Brunner et al56 reported an association between high 
levels of PRA (as measured by the renin–sodium profile) 
and the incidence of myocardial infarction in patients with 
HTN. Parikh et al57 based on the Framingham Heart Study 
provided some insights that all-cause mortality increased 
with higher plasma renin at baseline in the whole sample 
(standardized hazard ratio [HR] 1.14; P = 0.046) and in 
hypertensive patients (HR 1.16; P = 0.046) but that the 
strength of these associations decreased with the length of 
follow-up. On the other hand, plasma renin did not predict 
hard cardiovascular or coronary events.
RAS inhibition, limiting the hemodynamic effects of 
Ang II, reduces proteinuria and is renoprotective in the long 
term. The hemodynamic changes caused by RAS inhibitors 
partially contribute to the antiproteinuric effect. Loriga et al58 
in a trial of benazepril or valsartan showed direct   correlation 
between PRA and decrease in proteinuria,   indicating that 
renin may contribute to renal vasoconstriction and could be 
a further determinant of kidney damage besides a   promising 
target for renoprotection.58,59 Renal vascular   damage 
  involving the afferent arteriole may then cause the level 
of PRA to increase,60 thus, establishing a relation between 
increasing levels of PRA and the risk of a major coronary 
event. Baldoncini et al61 investigated the relationship between 
PRA and the urinary albumin excretion rate (UAER), an early 
marker of HTN-related renal changes, in human essential 
HTN. Their study demonstrated that the UAER is elevated 
in high-renin essential hypertensive patients, suggesting 
that high PRA accelerates the onset of early renal changes 
in human essential HTN.
The study by Yeyati and Adrogué62 support the existence 
of inappropriate activation of the RAS in humans with chronic 
renal disease. Such stimulation might play a   critical role in the 
pathophysiology of advanced renal injury. Their   investigation 
examined the PRA and the ratio of this   parameter to the simul-
taneously measured GFR (PRA/GFR) in normal   volunteers 
and in patients with chronic renal disease. A mean 10-fold 
increase in the PRA/GFR ratio was observed in patients with 
chronic renal disease as compared with normal volunteers. 
The observed   augmentation in PRA was not caused by the 
physiologic mechanisms aimed at conserving urinary sodium 
since a positive correlation was found between PRA/GFR 
and the fractional excretion of sodium as opposed to that of 
normal controls.
PRA and serum aldosterone levels are elevated in hyper-
tensive left ventricular (LV) hypertrophy and relate to LV 
mass index. In addition to BP, activation of the RAAS may 
be an important nonhemodynamic mechanism in the control 
of LV hypertrophy.63
Increased PRA plays an important role in the develop-
ment of HTN in subjects with central obesity. Licata et al64 
demonstrated that PRA was significantly higher in obese 
hypertensive than in obese normotensive subjects.
Aliskiren neutralized the increase in PRA associated 
with agents that stimulate renin release. This was studied 
in 1,093 patients with mild to moderate HTN and diastolic 
BP .95 mmHg and ,110 mmHg at randomization. Pooled 
analysis65 was done from four randomized,   double-blind, 
multicenter trials, lasting 8 weeks, in patients who had PRA 
measured at the baseline and at the end of the study. Aliskiren, 
150–600 mg, therapy caused significant   reductions in plasma 
inactivity of greater than 70%, vs placebo. In contrast, ramipril, 
hydrochlorothiazide (HCTZ), and   valsartan stimulated 
increases in PRA. When combined with ramipril, HCTZ, or 
valsartan, aliskiren continued to provide   significant reductions 
in PRA, thus, neutralizing the affect of antihypertensive agents 
that lead to increased activity of this biomarker.
Aliskiren was also studied alone or in combination with 
valsartan, in 1,797 patients with mild to moderate HTN, and 
showed reduced PRA and plasma aldosterone levels, both 
as monotherapy and as combination therapy, in an 8-week, 
randomized, double-blind, placebo-controlled study.66,67Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Aliskiren provides dose-dependent 
BP-lowering efficacy
Evidence for the efficacy of aliskiren is considered to be 
relatively strong, based on published, short-term, double-
blind, randomized, and controlled trials showing that 
aliskiren is as effective as other antihypertensive agents 
in reducing BP. When added to other antihypertensive 
agents, aliskiren provided additional BP lowering effects. 
Several trials have shown 150 mg or 300 mg daily dose of 
aliskiren (given for up to 8 weeks) to be superior to placebo 
in lowering BP.68
The efficacy of aliskiren has been tested in various 
clinical trials, including placebo-controlled studies and 
comparator studies with other antihypertensive agents, 
and in   combination with other antihypertensive agents. 
Several studies have compared aliskiren with other 
  antihypertensive agents, including HCTZ diuretics,69 
ARBs (valsartan,70 irbesartan,71 and losartan),72 ACEIs 
(ramipril and enalapril),73,74 and   dihydropyridine CCBs 
(amlodipine),75 in patients with uncomplicated HTN. There 
are no   comparative or combination trials with loop diuretics, 
α-blockers, α-agonists, or direct vasodilators. As mentioned 
earlier, HCTZ diuretics, ACEIs, and ARBs each cause reac-
tive increases in PRA. Therefore, it is hypothesized that 
these drugs used in combination with aliskiren will inhibit 
the increase in renin activity.
Patients with mean sitting diastolic BP (MSDBP) of 
95–109 mmHg were randomized to aliskiren 150, 300, 
or 600 mg or placebo once daily for 8 weeks.71 Patients 
completing this treatment phase entered into a 2-week, 
treatment-free withdrawal period. Office BP was recorded 
at baseline, weeks 2, 4, 6, and 8 of treatment, and 4 days 
and 2 weeks after cessation of treatment. A subgroup of 
patients underwent ambulatory BP monitoring. In total, 
672 patients were randomized to treatment. After 8 weeks, 
aliskiren 150, 300, and 600 mg significantly reduced mean 
sitting BP (systolic/diastolic) by 13.0/10.3, 14.7/11.1, and 
15.8/12.5 mmHg, respectively, vs 3.8/4.9 mmHg with 
placebo (all P , 0.0001 for systolic and diastolic BP). The 
BP-lowering effects of aliskiren persisted for up to 2 weeks 
after treatment withdrawal. Aliskiren significantly reduced 
the mean 24-hour ambulatory BP (P , 0.0001 vs placebo 
with all doses) exhibiting smooth and sustained effects and 
high trough-to-peak ratios. Aliskiren was well tolerated; 
overall adverse event rates were 40.1%, 46.7%, and 52.4% 
with aliskiren 150, 300, and 600 mg, respectively, and 43.0% 
with placebo. Few patients discontinued the treatment due 
to adverse events.71
Aliskiren monotherapy  
or in combination with HCTZ
Aliskiren monotherapy provided significant BP-lowering 
effects, which was greater when combined with HCTZ. 
The compensatory increase in PRA induced by HCTZ can 
be neutralized by renin inhibition with aliskiren. This was 
studied with varying doses of aliskiren (75, 150, or 300 mg) 
and HCTZ (6.25, 12.5, or 25 mg) alone and in combination 
in an 8-week, randomized, placebo-controlled trial of 2,776 
patients with mild to moderate HTN.76 The primary objec-
tives were to assess the changes in MSDBP and mean sitting 
systolic BP (MSSBP) at baseline. The effects on PRA were 
also assessed. BP reductions were greater with the combina-
tions than with monotherapy. Responders were defined as 
achieving a MSDBP of 90 mmHg and/or a .10 mmHg reduc-
tion from baseline. BP control was defined as a MSDBP of 
90 mmHg and a MSSBP of 140 mmHg. Superior responder 
rates occurred with aliskiren 300 mg (63.9%; P = 0.0005), 
HCTZ 12.5 and 25 mg (60.6% and 59.0%, respectively; for 
both P = 0.02), and all combination doses compared with pla-
cebo. Better control and responder rates for all combinations 
of aliskiren (75–300 mg) with HCTZ 25 mg and aliskiren 
300 mg/HCTZ 12.5 mg were superior to both monotherapies 
(P = 0.05). Aliskiren reduced the PRA by up to 65% from 
baseline. PRA decreased in all of the combination groups; 
however, HCTZ alone increased PRA by up to 72%.76
Aliskiren monotherapy  
or in combination with ARBs
Aliskiren used in combination with valsartan may provide 
additive and tolerable BP-lowering effects. Aliskiren and 
valsartan were investigated as monotherapy and in com-
bination in an 8-week, randomized, placebo-controlled, 
dose-escalation trial of 1,797 patients with uncomplicated 
HTN.65,77 Patients received either aliskiren 150 mg, valsartan 
160 mg, the combination of aliskiren 150 mg and valsartan 
160 mg, or placebo. After 4 weeks, all medication doses 
were doubled, and therapy was continued for an additional 
4 weeks. Seated trough cuff BP was measured at baseline, 
4th week, and 8th week. BP reductions with the combinations 
were greater than the reductions with both monotherapies. 
The combination of aliskiren 300 mg and valsartan 320 mg 
had statistically superior reductions in MSSBP and MSDBP 
compared with aliskiren 300 mg alone and valsartan 320 mg 
alone at week 8.77
Multiple studies have evaluated the efficacy and safety 
of aliskiren in comparison with various ARBs (irbesartan,71 
losartan).72 In a 4-week study that included ambulatory BP Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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monitoring, there was no statistical difference between the 
change in daytime systolic BP with 100 mg/d losartan and 
300 mg aliskiren. In another study, the antihypertensive 
efficacy of aliskiren 150 mg was found to be similar to 
that of irbesartan 150 mg/d, which at this dose increased 
both PRA (+116.3%) and plasma renin concentration 
(PRC, +107.0%).78
Aliskiren alone vs in combination 
with ramipril
Two trials have compared the BP-lowering effects of aliskiren 
with that of the ACEI ramipril. In hypertensive patients with 
diabetes, aliskiren (300 mg) was equally effective in lowering 
MSDBP (the primary efficacy variable) compared with ramipril 
(10 mg). A significantly greater reduction in sitting systolic 
BP was seen in aliskiren-treated patients. Similar results were 
obtained in a longer term (6 months) comparison of aliskiren 
and ramipril in hypertensive patients without diabetes. Ramipril 
also produced RAS activation. In one study, ramipril 10 mg 
increased both PRA (+110.6%) and PRC (+67.9%).79
Aliskiren monotherapy  
vs combination therapy  
with amlodipine
One study has assessed the efficacy and tolerability of 
aliskiren combined with a CCB. Patients showing an 
  inadequate response to amlodipine 5 mg/d were   randomized 
to continued therapy with amlodipine 5 mg, up-titration to 
amlodipine 10 mg, or the addition of aliskiren 150 mg to 
amlodipine 5 mg. Up-titration of amlodipine or addition 
of aliskiren resulted in significantly greater BP reduction 
than continuation of amlodipine 5 mg/d, with no   difference 
between the low-dose combination and high-dose   amlodipine. 
The 10-mg amlodipine dose was associated with a higher 
incidence of treatment-related peripheral edema (a dose-
dependent side effect of CCBs) compared with the low-dose 
combination (11.2% vs 2.1%).80
Dual RAS blockade  
and kidney diseases
Dual blockade of the RAS with losartan and aliskiren was 
beneficial in reducing albuminuria among patients with 
type 2 diabetes having HTN and nephropathy, as seen 
in aliskiren in the Evaluation of Proteinuria in Diabetes 
(AVOID) Trial,81 in which 599 subjects were initially 
administered losartan for 3 months, following which they 
were randomized to receive either aliskiren or placebo for 
6 months along with the ARB. The dose of aliskiren was 
150 mg for the first 3 months and was doubled during the 
subsequent 3 months. The early morning urine sample was 
evaluated for albumin–creatinine ratio. It was observed 
that the main albumin–creatinine ratio reduced by 20% 
in subjects on aliskiren as compared with placebo. Also, 
a 50% reduction in the ratio was noted in almost 1 of 4 
patients on aliskiren. Aliskiren also appeared to have a 
modest BP-lowering effect; however, the reduction in albu-
minuria was preserved after controlling for this change in 
BP. This is an important finding since many patients who 
receive angiotensin-receptor blockers or ACEIs still have 
progression of renal disease. These results are promising, 
and it will be of interest to see whether an ongoing clinical 
outcomes study of patients with DN confirms the superior-
ity of dual RAS blockade with an ARB and aliskiren vs 
ARB-based therapy alone.82
Conclusion
There are reasons to speculate that renin inhibition might 
prove to be a superior strategy for blocking the RAS 
compared with existing drugs. Evidence for the efficacy 
of aliskiren (a DRI) is considered to be relatively strong, 
based on published, short–term, double-blind, randomized, 
controlled trials showing that aliskiren is a potent inhibitor 
of renin and its bioavailability is sufficient to produce sus-
tained suppression of PRA and BP reduction after chronic 
oral dosing. This suppression is present whether the drug is 
given alone or in combination and persists after drug dis-
continuation. It is logical to assume that PRA suppression 
also leads to downstream suppression of Ang II formation. 
Although there are supportive data from animal studies, it 
is also unknown whether aliskiren will prove to be superior, 
equal, or inferior to ACEIs or ARBs in terms of end-organ 
protection. These are the key outstanding questions, the 
answers to which will ultimately determine the place of 
renin inhibition and aliskiren in the treatment of HTN and 
related cardiovascular disorders. A landmark clinical trials 
program, Aspire Higher, investigates the potential of aliskiren 
to move cardio-renal protection beyond that offered by ACEIs 
and ARBs. It includes 4 morbidity and mortality trials for 
aliskiren, in heart failure, DN, and prevention of cardio-
vascular outcomes in elderly. Given the well-demonstrated 
effectiveness of many antihypertensive agents in reducing 
cardiovascular end points, most clinicians need proof of either 
a significant superiority in preventing these end points or a 
compelling drug class benefit to identify the role of renin 
inhibition in the treatment of HTN.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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